SIStockInvestingSI.com

NASDAQ · DXCM · Medical Devices

DexCom, Inc. (DXCM) stock analysis

$80.26−6.39%Data as of Oct 21, 2026
  • DXCM lost 10.4% over the past month versus 0.0% for the S&P 500, ranking 457th of 497 S&P 500 stocks.
  • Over 12 months it returned +17.3%, 1.5 points ahead of the S&P 500, and trades 13.1% below its 52-week high.
  • In the last 30 days 0 analysts raised earnings estimates and 2 cut; forward EPS moved 0.0% (+1.5% over 90 days).
  • It sits in the Diagnostics, monitoring & imaging segment of the Healthcare Value Chain, where the 1-month median return is −3.1%.
  • The daily chart reads Trend transition · Unresolved structure (since Oct 6, 2026).
Market cap$30.3B
12-month return+17.3%
Forward P/E25.7×
Mean target vs price+20.2%

One-year price with 50- and 200-day averages

Open in Hub
57.868.378.889.3JanAprJulOct
80.2650-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

DXCM−10.4%
Sector median−8.7%
S&P 5000.0%
DXCM+13.9%
Sector median−5.4%
S&P 500+4.7%
DXCM+26.6%
Sector median−1.5%
S&P 500+8.7%
DXCM+17.3%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500457 / 497
1-month rank in the Nasdaq 10086 / 100
3-month rank in its sector · Healthcare183 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Trend transition · Unresolved structureAwaiting confirmation

Holding since Oct 6, 2026

  • Price and averages have mixed alignment
  • EMA50 is approximately flat
  • Volume exceeds 1.5× the prior 20-session average; supporting evidence only
  • Intermediate and long-term directions differ
  • Neither a stable trend nor a range is confirmed
This pattern on this stock

63 occurrences in 10 years. The median move over the next 20 sessions was +1.0%, positive 57% of the time, against +1.4% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$3.12
30-day change0.0%
90-day change+1.5%
Mean target$96.46 +20.2%
Raised (30d) 0Cut (30d) 2

26 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersMomentum, Profit

Behind peersValuation, Revisions

PeersABT · MDT · SYK · BSX

Where it sits in the supply chain

Healthcare Value Chain · Drugs & devices

Explore the full chain map in Hub
Its segment
Diagnostics, monitoring & imaging−3.1%
ABT−3.1%1 monthDXCM−10.4%1 monthGEHC+4.1%1 month

Continuous glucose monitors, diagnostics and imaging; the spread of GLP-1 drugs raised concern about diabetes-device demand.

Sells into
Hospitals & care delivery+8.4%
HCA+4.9%1 monthUNH+11.8%1 month
PBMs & pharmacies+9.3%
CVS+7.3%1 monthCI+11.2%1 monthUNH+11.8%1 month6618.HK+7.3%1 month

Also on: Medtech, Diagnostics & Care

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−22.8%
Volatility, 60D40.1%
From 52-week high−13.1%
From 52-week low+46.4%
Trailing P/E31.7×
Forward P/E25.7×

Themes

  • MedTech3M rank 28 / 90
ABTAbbott LaboratoriesUNHUnitedHealth GroupCVSCVS HealthCICignaMDTMedtronicSYKStrykerBSXBoston ScientificEWEdwards Lifesciences Corporatio

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗